BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Aron-wisnewsky J, Vigliotti C, Witjes J, Le P, Holleboom AG, Verheij J, Nieuwdorp M, Clément K. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol Hepatol 2020;17:279-97. [DOI: 10.1038/s41575-020-0269-9] [Cited by in Crossref: 103] [Cited by in F6Publishing: 103] [Article Influence: 51.5] [Reference Citation Analysis]
Number Citing Articles
1 Du F, Huang R, Lin D, Wang Y, Yang X, Huang X, Zheng B, Chen Z, Huang Y, Wang X, Chen F. Resveratrol Improves Liver Steatosis and Insulin Resistance in Non-alcoholic Fatty Liver Disease in Association With the Gut Microbiota. Front Microbiol 2021;12:611323. [PMID: 33708180 DOI: 10.3389/fmicb.2021.611323] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Yang SS, Chen YH, Hu JT, Chiu CF, Hung SW, Chang YC, Chiu CC, Chuang HL. Aldehyde Dehydrogenase Mutation Exacerbated High-Fat-Diet-Induced Nonalcoholic Fatty Liver Disease with Gut Microbiota Remodeling in Male Mice. Biology (Basel) 2021;10:737. [PMID: 34439969 DOI: 10.3390/biology10080737] [Reference Citation Analysis]
3 Houttu V, Csader S, Nieuwdorp M, Holleboom AG, Schwab U. Dietary Interventions in Patients With Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Front Nutr 2021;8:716783. [PMID: 34368214 DOI: 10.3389/fnut.2021.716783] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Ji Y, Yin Y, Sun L, Zhang W. The Molecular and Mechanistic Insights Based on Gut-Liver Axis: Nutritional Target for Non-Alcoholic Fatty Liver Disease (NAFLD) Improvement. Int J Mol Sci 2020;21:E3066. [PMID: 32357561 DOI: 10.3390/ijms21093066] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
5 Gao Y, Tian R, Liu H, Xue H, Zhang R, Han S, Ji L, Huang W, Zhan J, You Y. Research progress on intervention effect and mechanism of protocatechuic acid on nonalcoholic fatty liver disease. Crit Rev Food Sci Nutr 2021;:1-23. [PMID: 34142875 DOI: 10.1080/10408398.2021.1939265] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Mu H, Zhou Q, Yang R, Zeng J, Li X, Zhang R, Tang W, Li H, Wang S, Shen T, Huang X, Dou L, Dong J. Naringin Attenuates High Fat Diet Induced Non-alcoholic Fatty Liver Disease and Gut Bacterial Dysbiosis in Mice. Front Microbiol 2020;11:585066. [PMID: 33281780 DOI: 10.3389/fmicb.2020.585066] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
7 Luo ZH, Niu MW, Gong SH, Wu GY, Wang T, Wang FZ, Wei GQ, He ZK, Jiang Y, Chen P. Intestinal epithelial chemokine (C-C motif) ligand 7 overexpression protects against high fat diet-induced obesity and hepatic steatosis in mice. Chin Med J (Engl) 2020;133:1805-14. [PMID: 32649507 DOI: 10.1097/CM9.0000000000000915] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Machado AS, Oliveira JR, Lelis DF, de Paula AMB, Guimarães ALS, Andrade JMO, Brandi IV, Santos SHS. Oral Probiotic Bifidobacterium Longum Supplementation Improves Metabolic Parameters and Alters the Expression of the Renin-Angiotensin System in Obese Mice Liver. Biol Res Nurs 2021;23:100-8. [PMID: 32700545 DOI: 10.1177/1099800420942942] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
9 Mu HN, Zhou Q, Yang RY, Tang WQ, Li HX, Wang SM, Li J, Chen WX, Dong J. Caffeic acid prevents non-alcoholic fatty liver disease induced by a high-fat diet through gut microbiota modulation in mice. Food Res Int 2021;143:110240. [PMID: 33992352 DOI: 10.1016/j.foodres.2021.110240] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
10 Li H, Wang Q, Chen P, Zhou C, Zhang X, Chen L. Ursodeoxycholic Acid Treatment Restores Gut Microbiota and Alleviates Liver Inflammation in Non-Alcoholic Steatohepatitic Mouse Model. Front Pharmacol 2021;12:788558. [PMID: 34938193 DOI: 10.3389/fphar.2021.788558] [Reference Citation Analysis]
11 Sharma SP, Suk KT, Kim DJ. Significance of gut microbiota in alcoholic and non-alcoholic fatty liver diseases. World J Gastroenterol 2021; 27(37): 6161-6179 [PMID: 34712025 DOI: 10.3748/wjg.v27.i37.6161] [Reference Citation Analysis]
12 Li X, Tan C, Liu Y, Xu Y. Interactions between Food Hazards and Intestinal Barrier: Impact on Foodborne Diseases. J Agric Food Chem 2020;68:14728-38. [DOI: 10.1021/acs.jafc.0c07378] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Qian M, Liu J, Zhao D, Cai P, Pan C, Jia W, Gao Y, Zhang Y, Zhang N, Zhang Y, Zhang Q, Wu D, Shan C, Zhang M, Schnabl B, Yang S, Shen X, Wang L. Aryl Hydrocarbon Receptor Deficiency in Intestinal Epithelial Cells Aggravates Alcohol-Related Liver Disease. Cell Mol Gastroenterol Hepatol 2021;13:233-56. [PMID: 34454169 DOI: 10.1016/j.jcmgh.2021.08.014] [Reference Citation Analysis]
14 Arif M, Zhang C, Li X, Güngör C, Çakmak B, Arslantürk M, Tebani A, Özcan B, Subaş O, Zhou W, Piening B, Turkez H, Fagerberg L, Price N, Hood L, Snyder M, Nielsen J, Uhlen M, Mardinoglu A. iNetModels 2.0: an interactive visualization and database of multi-omics data. Nucleic Acids Res 2021;49:W271-6. [PMID: 33849075 DOI: 10.1093/nar/gkab254] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
15 Houron C, Ciocan D, Trainel N, Mercier-Nomé F, Hugot C, Spatz M, Perlemuter G, Cassard AM. Gut Microbiota Reshaped by Pectin Treatment Improves Liver Steatosis in Obese Mice. Nutrients 2021;13:3725. [PMID: 34835981 DOI: 10.3390/nu13113725] [Reference Citation Analysis]
16 Goto M, Azuma K, Arima H, Kaneko S, Higashi T, Motoyama K, Michihara A, Shimizu T, Kadowaki D, Maruyama T, Otagiri M, Iohara D, Hirayama F, Anraku M. Sacran, a sulfated polysaccharide, suppresses the absorption of lipids and modulates the intestinal flora in non-alcoholic steatohepatitis model rats. Life Sci 2021;268:118991. [PMID: 33417955 DOI: 10.1016/j.lfs.2020.118991] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Chiou WC, Chang BH, Tien HH, Cai YL, Fan YC, Chen WJ, Chu HF, Chen YH, Huang C. Synbiotic Intervention with an Adlay-Based Prebiotic and Probiotics Improved Diet-Induced Metabolic Disturbance in Mice by Modulation of the Gut Microbiota. Nutrients 2021;13:3161. [PMID: 34579036 DOI: 10.3390/nu13093161] [Reference Citation Analysis]
18 Jin Z, Sun Y, Yang T, Tan L, Lv P, Xu Q, Tao G, Qin S, Lu X, He Q. Nanocapsule-mediated sustained H2 release in the gut ameliorates metabolic dysfunction-associated fatty liver disease. Biomaterials 2021;276:121030. [PMID: 34298442 DOI: 10.1016/j.biomaterials.2021.121030] [Reference Citation Analysis]
19 Hu Q, Zhang W, Wu Z, Tian X, Xiang J, Li L, Li Z, Peng X, Wei S, Ma X, Zhao Y. Baicalin and the liver-gut system: Pharmacological bases explaining its therapeutic effects. Pharmacol Res 2021;165:105444. [PMID: 33493657 DOI: 10.1016/j.phrs.2021.105444] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
20 De Muynck K, Vanderborght B, Van Vlierberghe H, Devisscher L. The Gut-Liver Axis in Chronic Liver Disease: A Macrophage Perspective. Cells 2021;10:2959. [PMID: 34831182 DOI: 10.3390/cells10112959] [Reference Citation Analysis]
21 Du K, Li S, Li C, Li P, Miao C, Luo T, Qiu B, Ding W. Modeling nonalcoholic fatty liver disease on a liver lobule chip with dual blood supply. Acta Biomater 2021:S1742-7061(21)00444-X. [PMID: 34265474 DOI: 10.1016/j.actbio.2021.07.013] [Reference Citation Analysis]
22 Jiao N, Loomba R, Yang ZH, Wu D, Fang S, Bettencourt R, Lan P, Zhu R, Zhu L. Alterations in bile acid metabolizing gut microbiota and specific bile acid genes as a precision medicine to subclassify NAFLD. Physiol Genomics 2021;53:336-48. [PMID: 34151600 DOI: 10.1152/physiolgenomics.00011.2021] [Reference Citation Analysis]
23 Le Roy T, Moens de Hase E, Van Hul M, Paquot A, Pelicaen R, Régnier M, Depommier C, Druart C, Everard A, Maiter D, Delzenne NM, Bindels LB, de Barsy M, Loumaye A, Hermans MP, Thissen JP, Vieira-Silva S, Falony G, Raes J, Muccioli GG, Cani PD. Dysosmobacter welbionis is a newly isolated human commensal bacterium preventing diet-induced obesity and metabolic disorders in mice. Gut 2021:gutjnl-2020-323778. [PMID: 34108237 DOI: 10.1136/gutjnl-2020-323778] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Castillo-Castro C, Martagón-Rosado AJ, Ortiz-Lopez R, Garrido-Treviño LF, Villegas-Albo M, Bosques-Padilla FJ. Promising diagnostic biomarkers of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: From clinical proteomics to microbiome. World J Hepatol 2021; 13(11): 1494-1511 [PMID: 34904026 DOI: 10.4254/wjh.v13.i11.1494] [Reference Citation Analysis]
25 Gao Y, Zhang J, Xiao X, Ren Y, Yan X, Yue J, Wang T, Wu Z, Lv Y, Wu R. The Role of Gut Microbiota in Duodenal-Jejunal Bypass Surgery-Induced Improvement of Hepatic Steatosis in HFD-Fed Rats. Front Cell Infect Microbiol 2021;11:640448. [PMID: 33869077 DOI: 10.3389/fcimb.2021.640448] [Reference Citation Analysis]
26 Arroyave-Ospina JC, Wu Z, Geng Y, Moshage H. Role of Oxidative Stress in the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Implications for Prevention and Therapy. Antioxidants (Basel) 2021;10:174. [PMID: 33530432 DOI: 10.3390/antiox10020174] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 15.0] [Reference Citation Analysis]
27 Lang S, Schnabl B. Microbiota and Fatty Liver Disease-the Known, the Unknown, and the Future. Cell Host Microbe 2020;28:233-44. [PMID: 32791115 DOI: 10.1016/j.chom.2020.07.007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 20.0] [Reference Citation Analysis]
28 Ramadan MS, Russo V, Nigro G, Durante-Mangoni E, Zampino R. Interplay between Heart Disease and Metabolic Steatosis: A Contemporary Perspective. J Clin Med 2021;10:1569. [PMID: 33917867 DOI: 10.3390/jcm10081569] [Reference Citation Analysis]
29 Jiang T, Guo XJ, Tu LP, Lu Z, Cui J, Ma XX, Hu XJ, Yao XH, Cui LT, Li YZ, Huang JB, Xu JT. Application of computer tongue image analysis technology in the diagnosis of NAFLD. Comput Biol Med 2021;135:104622. [PMID: 34242868 DOI: 10.1016/j.compbiomed.2021.104622] [Reference Citation Analysis]
30 Seif El-Din SH, Salem MB, El-Lakkany NM, Hammam OA, Nasr SM, Okasha H, Ahmed LA, Saleh S, Botros SS. Early intervention with probiotics and metformin alleviates liver injury in NAFLD rats via targeting gut microbiota dysbiosis and p-AKT/mTOR/LC-3II pathways. Hum Exp Toxicol 2021;40:1496-509. [PMID: 33678036 DOI: 10.1177/0960327121999445] [Reference Citation Analysis]
31 Schönborn JW, Stewart FA, Enriquez KM, Akhtar I, Droste A, Waschina S, Beller M. Modeling Drosophila gut microbe interactions reveals metabolic interconnectivity. iScience 2021;24:103216. [PMID: 34712918 DOI: 10.1016/j.isci.2021.103216] [Reference Citation Analysis]
32 He LH, Yao DH, Wang LY, Zhang L, Bai XL. Gut Microbiome-Mediated Alteration of Immunity, Inflammation, and Metabolism Involved in the Regulation of Non-alcoholic Fatty Liver Disease. Front Microbiol 2021;12:761836. [PMID: 34795655 DOI: 10.3389/fmicb.2021.761836] [Reference Citation Analysis]
33 Zhou J, Tripathi M, Sinha RA, Singh BK, Yen PM. Gut microbiota and their metabolites in the progression of non-alcoholic fatty liver disease. Hepatoma Res 2021;7:11. [PMID: 33490737 DOI: 10.20517/2394-5079.2020.134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
34 Kasper P, Martin A, Lang S, Kütting F, Goeser T, Demir M, Steffen HM. NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol 2021;110:921-37. [PMID: 32696080 DOI: 10.1007/s00392-020-01709-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 11.0] [Reference Citation Analysis]
35 Głuszyńska P, Lemancewicz D, Dzięcioł JB, Razak Hady H. Non-Alcoholic Fatty Liver Disease (NAFLD) and Bariatric/Metabolic Surgery as Its Treatment Option: A Review. J Clin Med 2021;10:5721. [PMID: 34945016 DOI: 10.3390/jcm10245721] [Reference Citation Analysis]
36 Santos-laso A, Gutiérrez-larrañaga M, Alonso-peña M, Medina JM, Iruzubieta P, Arias-loste MT, López-hoyos M, Crespo J. Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets. Biomedicines 2022;10:46. [DOI: 10.3390/biomedicines10010046] [Reference Citation Analysis]
37 Jadhav K, Cohen TS. Can You Trust Your Gut? Front Endocrinol (Lausanne). 2020;11:592157. [PMID: 33193105 DOI: 10.3389/fendo.2020.592157] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
38 Martín-Mateos R, Albillos A. The Role of the Gut-Liver Axis in Metabolic Dysfunction-Associated Fatty Liver Disease. Front Immunol 2021;12:660179. [PMID: 33936094 DOI: 10.3389/fimmu.2021.660179] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
39 Hoozemans J, de Brauw M, Nieuwdorp M, Gerdes V. Gut Microbiome and Metabolites in Patients with NAFLD and after Bariatric Surgery: A Comprehensive Review. Metabolites 2021;11:353. [PMID: 34072995 DOI: 10.3390/metabo11060353] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Yoha KS, Nida S, Dutta S, Moses JA, Anandharamakrishnan C. Targeted Delivery of Probiotics: Perspectives on Research and Commercialization. Probiotics Antimicrob Proteins 2021. [PMID: 33904011 DOI: 10.1007/s12602-021-09791-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Hyun CK. Molecular and Pathophysiological Links between Metabolic Disorders and Inflammatory Bowel Diseases. Int J Mol Sci 2021;22:9139. [PMID: 34502047 DOI: 10.3390/ijms22179139] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
42 Sui G, Jia L, Quan D, Zhao N, Yang G. Activation of the gut microbiota-kynurenine-liver axis contributes to the development of nonalcoholic hepatic steatosis in nondiabetic adults. Aging (Albany NY) 2021;13:21309-24. [PMID: 34473644 DOI: 10.18632/aging.203460] [Reference Citation Analysis]
43 Negi CK, Khan S, Dirven H, Bajard L, Bláha L. Flame Retardants-Mediated Interferon Signaling in the Pathogenesis of Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2021;22:4282. [PMID: 33924165 DOI: 10.3390/ijms22084282] [Reference Citation Analysis]
44 Li J, Jin H, Yan X, Shao D, Hu X, Shi J. The anti-obesity effects exerted by different fractions of Artemisia sphaerocephala Krasch polysaccharide in diet-induced obese mice. Int J Biol Macromol 2021;182:825-37. [PMID: 33864863 DOI: 10.1016/j.ijbiomac.2021.04.070] [Reference Citation Analysis]
45 Jiang D, Zhang J, Lin S, Wang Y, Chen Y, Fan J. Prolyl Endopeptidase Gene Disruption Improves Gut Dysbiosis and Non-alcoholic Fatty Liver Disease in Mice Induced by a High-Fat Diet. Front Cell Dev Biol 2021;9:628143. [PMID: 34095107 DOI: 10.3389/fcell.2021.628143] [Reference Citation Analysis]
46 Peiseler M, Tacke F. Inflammatory Mechanisms Underlying Nonalcoholic Steatohepatitis and the Transition to Hepatocellular Carcinoma. Cancers (Basel) 2021;13:730. [PMID: 33578800 DOI: 10.3390/cancers13040730] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Scapaticci S, D'Adamo E, Mohn A, Chiarelli F, Giannini C. Non-Alcoholic Fatty Liver Disease in Obese Youth With Insulin Resistance and Type 2 Diabetes.Front Endocrinol (Lausanne). 2021;12:639548. [PMID: 33889132 DOI: 10.3389/fendo.2021.639548] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
48 Purssell H, Whorwell PJ, Athwal VS, Vasant DH. Non-alcoholic fatty liver disease in irritable bowel syndrome: More than a coincidence? World J Hepatol 2021; 13(12): 1816-1827 [DOI: 10.4254/wjh.v13.i12.1816] [Reference Citation Analysis]
49 Niederseer D, Wernly B, Aigner E, Stickel F, Datz C. NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations. J Clin Med 2021;10:467. [PMID: 33530440 DOI: 10.3390/jcm10030467] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
50 Aron-Wisnewsky J, Warmbrunn MV, Nieuwdorp M, Clément K. Nonalcoholic Fatty Liver Disease: Modulating Gut Microbiota to Improve Severity? Gastroenterology 2020;158:1881-98. [PMID: 32044317 DOI: 10.1053/j.gastro.2020.01.049] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 12.5] [Reference Citation Analysis]
51 Lee YA, Friedman SL. Inflammatory and fibrotic mechanisms in NAFLD-Implications for new treatment strategies. J Intern Med 2021. [PMID: 34564899 DOI: 10.1111/joim.13380] [Reference Citation Analysis]
52 Goto M, Iohara D, Michihara A, Ifuku S, Azuma K, Kadowaki D, Maruyama T, Otagiri M, Hirayama F, Anraku M. Effects of surface-deacetylated chitin nanofibers on non-alcoholic steatohepatitis model rats and their gut microbiota. Int J Biol Macromol 2020;164:659-66. [PMID: 32698063 DOI: 10.1016/j.ijbiomac.2020.07.184] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
53 Alili R, Belda E, Le P, Wirth T, Zucker JD, Prifti E, Clément K. Exploring Semi-Quantitative Metagenomic Studies Using Oxford Nanopore Sequencing: A Computational and Experimental Protocol. Genes (Basel) 2021;12:1496. [PMID: 34680891 DOI: 10.3390/genes12101496] [Reference Citation Analysis]
54 Li B, Qiu H, Zheng N, Wu G, Gu Y, Zhong J, Hong Y, Ma J, Zhou W, Sheng L, Li H. Integrated Metagenomic and Transcriptomic Analyses Reveal the Dietary Dependent Recovery of Host Metabolism From Antibiotic Exposure. Front Cell Dev Biol 2021;9:680174. [PMID: 34222250 DOI: 10.3389/fcell.2021.680174] [Reference Citation Analysis]
55 Nawrot M, Peschard S, Lestavel S, Staels B. Intestine-liver crosstalk in Type 2 Diabetes and non-alcoholic fatty liver disease. Metabolism 2021;123:154844. [PMID: 34343577 DOI: 10.1016/j.metabol.2021.154844] [Reference Citation Analysis]
56 Yang XF, Lu M, You L, Gen H, Yuan L, Tian T, Li CY, Xu K, Hou J, Lei M. Herbal therapy for ameliorating nonalcoholic fatty liver disease via rebuilding the intestinal microecology. Chin Med 2021;16:62. [PMID: 34315516 DOI: 10.1186/s13020-021-00470-x] [Reference Citation Analysis]
57 Madatali Abuwani A, Priyadarshini Dash S, Ganesan R, Renu K, Vellingiri B, Kandasamy S, C R SR, Valsala Gopalakrishnan A. Gut microbiome and metabolic response in non-alcoholic fatty liver disease. Clin Chim Acta 2021;523:304-14. [PMID: 34666025 DOI: 10.1016/j.cca.2021.10.014] [Reference Citation Analysis]
58 Juárez-Fernández M, Porras D, García-Mediavilla MV, Román-Sagüillo S, González-Gallego J, Nistal E, Sánchez-Campos S. Aging, Gut Microbiota and Metabolic Diseases: Management through Physical Exercise and Nutritional Interventions. Nutrients 2020;13:E16. [PMID: 33374578 DOI: 10.3390/nu13010016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
59 Chen J, Vitetta L. Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications. Int J Mol Sci 2020;21:E5214. [PMID: 32717871 DOI: 10.3390/ijms21155214] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
60 Caballano-infantes E, García-garcía A, Lopez-gomez C, Cueto A, Robles-diaz M, Ortega-alonso A, Martín-reyes F, Alvarez-alvarez I, Arranz-salas I, Ruiz-cabello F, Lucena IM, García-fuentes E, Andrade RJ, García-cortes M. Differential iNKT and T Cells Activation in Non-Alcoholic Fatty Liver Disease and Drug-Induced Liver Injury. Biomedicines 2022;10:55. [DOI: 10.3390/biomedicines10010055] [Reference Citation Analysis]
61 Zeybel M, Altay O, Arif M, Li X, Yang H, Fredolini C, Akyildiz M, Saglam B, Gonenli MG, Ural D, Kim W, Schwenk JM, Zhang C, Shoaie S, Nielsen J, Uhlén M, Borén J, Mardinoglu A. Combined metabolic activators therapy ameliorates liver fat in nonalcoholic fatty liver disease patients. Mol Syst Biol 2021;17:e10459. [PMID: 34694070 DOI: 10.15252/msb.202110459] [Reference Citation Analysis]
62 Chiriac S, Stanciu C, Girleanu I, Cojocariu C, Sfarti C, Singeap AM, Cuciureanu T, Huiban L, Muzica CM, Zenovia S, Nastasa R, Trifan A. Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases: The Heart of the Matter. Can J Gastroenterol Hepatol 2021;2021:6696857. [PMID: 33505944 DOI: 10.1155/2021/6696857] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
63 Wang T, Guo XK, Xu H. Disentangling the Progression of Non-alcoholic Fatty Liver Disease in the Human Gut Microbiota. Front Microbiol 2021;12:728823. [PMID: 34721326 DOI: 10.3389/fmicb.2021.728823] [Reference Citation Analysis]
64 Amerikanou C, Kanoni S, Kaliora AC, Barone A, Bjelan M, D'auria G, Gioxari A, Gosalbes MJ, Mouchti S, Stathopoulou MG, Soriano B, Stojanoski S, Banerjee R, Halabalaki M, Mikropoulou EV, Kannt A, Lamont J, Llorens C, Marascio F, Marascio M, Roig FJ, Smyrnioudis I, Varlamis I, Visvikis‐siest S, Vukic M, Milic N, Medic‐stojanoska M, Cesarini L, Campolo J, Gastaldelli A, Deloukas P, Trivella MG, Francino MP, Dedoussis GV; MAST4HEALTH consortium. Effect of Mastiha supplementation on NAFLD: The MAST4HEALTH Randomised, Controlled Trial. Mol Nutr Food Res 2021;65:2001178. [DOI: 10.1002/mnfr.202001178] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
65 Jiang Y, Chowdhury S, Xu BH, Meybodi MA, Damiris K, Devalaraju S, Pyrsopoulos N. Nonalcoholic fatty liver disease is associated with worse intestinal complications in patients hospitalized for Clostridioides difficile infection. World J Hepatol 2021; 13(11): 1777-1790 [PMID: 34904045 DOI: 10.4254/wjh.v13.i11.1777] [Reference Citation Analysis]
66 Lira MMP, de Medeiros Filho JEM, Baccin Martins VJ, da Silva G, de Oliveira Junior FA, de Almeida Filho ÉJB, Silva AS, Henrique da Costa-Silva J, de Brito Alves JL. Association of worsening of nonalcoholic fatty liver disease with cardiometabolic function and intestinal bacterial overgrowth: A cross-sectional study. PLoS One 2020;15:e0237360. [PMID: 32845887 DOI: 10.1371/journal.pone.0237360] [Reference Citation Analysis]
67 Dahl WJ, Rivero Mendoza D, Lambert JM. Diet, nutrients and the microbiome. Prog Mol Biol Transl Sci 2020;171:237-63. [PMID: 32475524 DOI: 10.1016/bs.pmbts.2020.04.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
68 Hrncir T, Hrncirova L, Kverka M, Hromadka R, Machova V, Trckova E, Kostovcikova K, Kralickova P, Krejsek J, Tlaskalova-Hogenova H. Gut Microbiota and NAFLD: Pathogenetic Mechanisms, Microbiota Signatures, and Therapeutic Interventions. Microorganisms 2021;9:957. [PMID: 33946843 DOI: 10.3390/microorganisms9050957] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
69 Møller S, Kimer N, Kronborg T, Grandt J, Hove JD, Barløse M, Gluud LL. Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Overlapping Mechanisms. Semin Liver Dis 2021;41:235-47. [PMID: 33992031 DOI: 10.1055/s-0041-1725022] [Reference Citation Analysis]
70 Vancells Lujan P, Viñas Esmel E, Sacanella Meseguer E. Overview of Non-Alcoholic Fatty Liver Disease (NAFLD) and the Role of Sugary Food Consumption and Other Dietary Components in Its Development. Nutrients 2021;13:1442. [PMID: 33923255 DOI: 10.3390/nu13051442] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
71 Zhang Y, Li JX, Zhang Y, Wang YL. Intestinal microbiota participates in nonalcoholic fatty liver disease progression by affecting intestinal homeostasis . World J Clin Cases 2021; 9(23): 6654-6662 [PMID: 34447812 DOI: 10.12998/wjcc.v9.i23.6654] [Reference Citation Analysis]
72 Fougerat A, Montagner A, Loiseau N, Guillou H, Wahli W. Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease. Cells 2020;9:E1638. [PMID: 32650421 DOI: 10.3390/cells9071638] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
73 Fernandez-Cantos MV, Garcia-Morena D, Iannone V, El-Nezami H, Kolehmainen M, Kuipers OP. Role of microbiota and related metabolites in gastrointestinal tract barrier function in NAFLD. Tissue Barriers 2021;:1879719. [PMID: 34280073 DOI: 10.1080/21688370.2021.1879719] [Reference Citation Analysis]
74 Martínez-Montoro JI, Cornejo-Pareja I, Gómez-Pérez AM, Tinahones FJ. Impact of Genetic Polymorphism on Response to Therapy in Non-Alcoholic Fatty Liver Disease. Nutrients 2021;13:4077. [PMID: 34836332 DOI: 10.3390/nu13114077] [Reference Citation Analysis]
75 Ipsen DH, Agerskov RH, Klaebel JH, Lykkesfeldt J, Tveden-Nyborg P. The development of nonalcoholic steatohepatitis is subjected to breeder dependent variation in guinea pigs. Sci Rep 2021;11:2955. [PMID: 33536590 DOI: 10.1038/s41598-021-82643-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
76 Malnick SDH, Fisher D, Somin M, Neuman MG. Treating the Metabolic Syndrome by Fecal Transplantation-Current Status. Biology (Basel) 2021;10:447. [PMID: 34065241 DOI: 10.3390/biology10050447] [Reference Citation Analysis]
77 Tsai HJ, Tsai YC, Hung WW, Hung WC, Chang CC, Dai CY. Gut Microbiota and Non-Alcoholic Fatty Liver Disease Severity in Type 2 Diabetes Patients. J Pers Med 2021;11:238. [PMID: 33807075 DOI: 10.3390/jpm11030238] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
78 Oh JH, Lee JH, Cho MS, Kim H, Chun J, Lee JH, Yoon Y, Kang W. Characterization of Gut Microbiome in Korean Patients with Metabolic Associated Fatty Liver Disease. Nutrients 2021;13:1013. [PMID: 33801023 DOI: 10.3390/nu13031013] [Reference Citation Analysis]
79 Al-Jameel SS. Association of diabetes and microbiota: An update. Saudi J Biol Sci 2021;28:4446-54. [PMID: 34354429 DOI: 10.1016/j.sjbs.2021.04.041] [Reference Citation Analysis]
80 Van Hul M, Le Roy T, Prifti E, Dao MC, Paquot A, Zucker JD, Delzenne NM, Muccioli G, Clément K, Cani PD. From correlation to causality: the case of Subdoligranulum. Gut Microbes 2020;12:1-13. [PMID: 33323004 DOI: 10.1080/19490976.2020.1849998] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
81 Xiang J, Zhang Z, Xie H, Zhang C, Bai Y, Cao H, Che Q, Guo J, Su Z. Effect of different bile acids on the intestine through enterohepatic circulation based on FXR. Gut Microbes 2021;13:1949095. [PMID: 34313539 DOI: 10.1080/19490976.2021.1949095] [Reference Citation Analysis]
82 Zwartjes MSZ, Gerdes VEA, Nieuwdorp M. The Role of Gut Microbiota and Its Produced Metabolites in Obesity, Dyslipidemia, Adipocyte Dysfunction, and Its Interventions. Metabolites 2021;11:531. [PMID: 34436472 DOI: 10.3390/metabo11080531] [Reference Citation Analysis]
83 Ji X, Chen M, Zhao M, Song Y, Lin Y, Yin H, Zhao L. Effects of chitooligosaccharides on the rebalance of gut microorganisms and their metabolites in patients with nonalcoholic fatty liver disease. Journal of Functional Foods 2021;77:104333. [DOI: 10.1016/j.jff.2020.104333] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
84 Vijay A, Valdes AM. Role of the gut microbiome in chronic diseases: a narrative review. Eur J Clin Nutr 2021. [PMID: 34584224 DOI: 10.1038/s41430-021-00991-6] [Reference Citation Analysis]
85 Li R, Palmiotti A, de Vries HD, Hovingh MV, Koehorst M, Mulder NL, Zhang Y, Kats K, Bloks VW, Fu J, Verkade HJ, de Boer JF, Kuipers F. Low production of 12α-hydroxylated bile acids prevents hepatic steatosis in Cyp2c70-/- mice by reducing fat absorption. J Lipid Res 2021;:100134. [PMID: 34626589 DOI: 10.1016/j.jlr.2021.100134] [Reference Citation Analysis]
86 Massart J, Begriche K, Fromenty B. Cytochrome P450 2E1 should not be neglected for acetaminophen-induced liver injury in metabolic diseases with altered insulin levels or glucose homeostasis. Clin Res Hepatol Gastroenterol 2021;45:101470. [PMID: 32571750 DOI: 10.1016/j.clinre.2020.05.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
87 Yang JW, Ji HF. Phytosterols as bioactive food components against nonalcoholic fatty liver disease. Crit Rev Food Sci Nutr 2021;:1-12. [PMID: 34871105 DOI: 10.1080/10408398.2021.2006137] [Reference Citation Analysis]
88 Han H, Jiang Y, Wang M, Melaku M, Liu L, Zhao Y, Everaert N, Yi B, Zhang H. Intestinal dysbiosis in nonalcoholic fatty liver disease (NAFLD): focusing on the gut-liver axis. Crit Rev Food Sci Nutr 2021;:1-18. [PMID: 34404276 DOI: 10.1080/10408398.2021.1966738] [Reference Citation Analysis]
89 De A, Ahmad N, Mehta M, Singh P, Duseja A. NAFLD Vs MAFLD - It is not the name but the disease that decides the outcome in fatty liver. J Hepatol 2021:S0168-8278(21)02032-8. [PMID: 34530064 DOI: 10.1016/j.jhep.2021.09.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
90 Knudsen C, Arroyo J, Even M, Cauquil L, Pascal G, Fernandez X, Lavigne F, Davail S, Combes S, Ricaud K. The intestinal microbial composition in Greylag geese differs with steatosis induction mode: spontaneous or induced by overfeeding. Anim Microbiome 2021;3:6. [PMID: 33499980 DOI: 10.1186/s42523-020-00067-z] [Reference Citation Analysis]
91 Vanuytsel T, Tack J, Farre R. The Role of Intestinal Permeability in Gastrointestinal Disorders and Current Methods of Evaluation. Front Nutr 2021;8:717925. [PMID: 34513903 DOI: 10.3389/fnut.2021.717925] [Reference Citation Analysis]
92 Masoodi M, Gastaldelli A, Hyötyläinen T, Arretxe E, Alonso C, Gaggini M, Brosnan J, Anstee QM, Millet O, Ortiz P, Mato JM, Dufour JF, Orešič M. Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34508238 DOI: 10.1038/s41575-021-00502-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
93 Kotlyarov S, Bulgakov A. Lipid Metabolism Disorders in the Comorbid Course of Nonalcoholic Fatty Liver Disease and Chronic Obstructive Pulmonary Disease. Cells 2021;10:2978. [PMID: 34831201 DOI: 10.3390/cells10112978] [Reference Citation Analysis]
94 Zhang X, Coker OO, Chu ES, Fu K, Lau HCH, Wang YX, Chan AWH, Wei H, Yang X, Sung JJY, Yu J. Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites. Gut 2021;70:761-74. [PMID: 32694178 DOI: 10.1136/gutjnl-2019-319664] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 14.0] [Reference Citation Analysis]
95 Yang Y, Jiang X, Pandol SJ, Han YP, Zheng X. Green Plant Pigment, Chlorophyllin, Ameliorates Non-alcoholic Fatty Liver Diseases (NAFLDs) Through Modulating Gut Microbiome in Mice. Front Physiol 2021;12:739174. [PMID: 34764881 DOI: 10.3389/fphys.2021.739174] [Reference Citation Analysis]
96 Kavyani M, Saleh-Ghadimi S, Dehghan P, Abbasalizad Farhangi M, Khoshbaten M. Co-supplementation of camelina oil and a prebiotic is more effective for in improving cardiometabolic risk factors and mental health in patients with NAFLD: a randomized clinical trial. Food Funct 2021. [PMID: 34338703 DOI: 10.1039/d1fo00448d] [Reference Citation Analysis]
97 Ruuskanen MO, Åberg F, Männistö V, Havulinna AS, Méric G, Liu Y, Loomba R, Vázquez-Baeza Y, Tripathi A, Valsta LM, Inouye M, Jousilahti P, Salomaa V, Jain M, Knight R, Lahti L, Niiranen TJ. Links between gut microbiome composition and fatty liver disease in a large population sample. Gut Microbes 2021;13:1-22. [PMID: 33651661 DOI: 10.1080/19490976.2021.1888673] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
98 Gu X, Lu Q, Zhang C, Tang Z, Chu L. Clinical Application and Progress of Fecal Microbiota Transplantation in Liver Diseases: A Review. Semin Liver Dis 2021. [PMID: 34261137 DOI: 10.1055/s-0041-1732319] [Reference Citation Analysis]
99 Villard A, Boursier J, Andriantsitohaina R. Bacterial and eukaryotic extracellular vesicles and nonalcoholic fatty liver disease: new players in the gut-liver axis? Am J Physiol Gastrointest Liver Physiol 2021;320:G485-95. [PMID: 33471632 DOI: 10.1152/ajpgi.00362.2020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
100 Aron-Wisnewsky J, Warmbrunn MV, Nieuwdorp M, Clément K. Metabolism and Metabolic Disorders and the Microbiome: The Intestinal Microbiota Associated With Obesity, Lipid Metabolism, and Metabolic Health-Pathophysiology and Therapeutic Strategies. Gastroenterology 2021;160:573-99. [PMID: 33253685 DOI: 10.1053/j.gastro.2020.10.057] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
101 Jiang J, Xiong J, Ni J, Chen C, Wang K. Live Combined B. subtilis and E. faecium Alleviate Liver Inflammation, Improve Intestinal Barrier Function, and Modulate Gut Microbiota in Mice with Non-Alcoholic Fatty Liver Disease. Med Sci Monit 2021;27:e931143. [PMID: 34482357 DOI: 10.12659/MSM.931143] [Reference Citation Analysis]
102 Xia F, Xiang S, Chen Z, Song L, Li Y, Liao Z, Ge B, Zhou B. The probiotic effects of AB23A on high-fat-diet-induced non-alcoholic fatty liver disease in mice may be associated with suppressing the serum levels of lipopolysaccharides and branched-chain amino acids. Arch Biochem Biophys 2021;714:109080. [PMID: 34742934 DOI: 10.1016/j.abb.2021.109080] [Reference Citation Analysis]
103 Yang M, Zhang CY. G protein-coupled receptors as potential targets for nonalcoholic fatty liver disease treatment. World J Gastroenterol 2021; 27(8): 677-691 [PMID: 33716447 DOI: 10.3748/wjg.v27.i8.677] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
104 Juárez-Fernández M, Porras D, Petrov P, Román-Sagüillo S, García-Mediavilla MV, Soluyanova P, Martínez-Flórez S, González-Gallego J, Nistal E, Jover R, Sánchez-Campos S. The Synbiotic Combination of Akkermansia muciniphila and Quercetin Ameliorates Early Obesity and NAFLD through Gut Microbiota Reshaping and Bile Acid Metabolism Modulation. Antioxidants (Basel) 2021;10:2001. [PMID: 34943104 DOI: 10.3390/antiox10122001] [Reference Citation Analysis]
105 Nakashima A, Kato K, Ohkido I, Yokoo T. Role and Treatment of Insulin Resistance in Patients with Chronic Kidney Disease: A Review. Nutrients 2021;13:4349. [PMID: 34959901 DOI: 10.3390/nu13124349] [Reference Citation Analysis]
106 Wegermann K, Suzuki A, Mavis AM, Abdelmalek MF, Diehl AM, Moylan CA. Tackling Nonalcoholic Fatty Liver Disease: Three Targeted Populations. Hepatology 2021;73:1199-206. [PMID: 32865242 DOI: 10.1002/hep.31533] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
107 Yan J, Sheng L, Li H. Akkermansia muciniphila: is it the Holy Grail for ameliorating metabolic diseases? Gut Microbes 2021;13:1984104. [PMID: 34674606 DOI: 10.1080/19490976.2021.1984104] [Reference Citation Analysis]
108 Zhang T, Zhu G, Lu B, Qian Z, Peng Q. Protein corona formed in the gastrointestinal tract and its impacts on oral delivery of nanoparticles. Med Res Rev 2021;41:1835-50. [DOI: 10.1002/med.21767] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
109 Wei L, Cheng X, Luo Y, Yang R, Lei Z, Jiang H, Chen L. Lean non-alcoholic fatty liver disease and risk of incident diabetes in a euglycaemic population undergoing health check-ups: A cohort study. Diabetes & Metabolism 2021;47:101200. [DOI: 10.1016/j.diabet.2020.08.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
110 Lanthier N, Rodriguez J, Nachit M, Hiel S, Trefois P, Neyrinck AM, Cani PD, Bindels LB, Thissen JP, Delzenne NM. Microbiota analysis and transient elastography reveal new extra-hepatic components of liver steatosis and fibrosis in obese patients. Sci Rep 2021;11:659. [PMID: 33436764 DOI: 10.1038/s41598-020-79718-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
111 Filipovic B, Lukic S, Mijac D, Marjanovic-Haljilji M, Vojnovic M, Bogdanovic J, Glisic T, Filipovic N, Al Kiswani J, Djokovic A, Kapor S, Kapor S, Bukumiric Z, Starcevic A. The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2021;22:13219. [PMID: 34948020 DOI: 10.3390/ijms222413219] [Reference Citation Analysis]
112 Hernández-Ceballos W, Cordova-Gallardo J, Mendez-Sanchez N. Gut Microbiota in Metabolic-associated Fatty Liver Disease and in Other Chronic Metabolic Diseases. J Clin Transl Hepatol 2021;9:227-38. [PMID: 34007805 DOI: 10.14218/JCTH.2020.00131] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
113 Yang R, Shang J, Zhou Y, Liu W, Tian Y, Shang H. Effects of probiotics on nonalcoholic fatty liver disease: a systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol 2021;15:1401-9. [PMID: 34877910 DOI: 10.1080/17474124.2022.2016391] [Reference Citation Analysis]
114 Xu J, Zhang JN, Sun BH, Liu Q, Ma J, Zhang Q, Liu YX, Chen N, Chen F. The role of genotype and diet in shaping gut microbiome in a genetic vitamin A deficient mouse model. J Genet Genomics 2021:S1673-8527(21)00299-X. [PMID: 34537414 DOI: 10.1016/j.jgg.2021.08.015] [Reference Citation Analysis]
115 Lonardo A. Renaming NAFLD to MAFLD: Could the LDE System Assist in This Transition? J Clin Med 2021;10:492. [PMID: 33572544 DOI: 10.3390/jcm10030492] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
116 Sakurai Y, Kubota N, Yamauchi T, Kadowaki T. Role of Insulin Resistance in MAFLD. Int J Mol Sci 2021;22:4156. [PMID: 33923817 DOI: 10.3390/ijms22084156] [Reference Citation Analysis]
117 Sotiropoulou M, Katsaros I, Vailas M, Lidoriki I, Papatheodoridis GV, Kostomitsopoulos NG, Valsami G, Tsaroucha A, Schizas D. Nonalcoholic fatty liver disease: The role of quercetin and its therapeutic implications. Saudi J Gastroenterol 2021;27:319-30. [PMID: 34810376 DOI: 10.4103/sjg.sjg_249_21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
118 Liptak R, Gromova B, Gardlik R. Fecal Microbiota Transplantation as a Tool for Therapeutic Modulation of Non-gastrointestinal Disorders. Front Med (Lausanne) 2021;8:665520. [PMID: 34557498 DOI: 10.3389/fmed.2021.665520] [Reference Citation Analysis]
119 Shi A, Li T, Zheng Y, Song Y, Wang H, Wang N, Dong L, Shi H. Chlorogenic Acid Improves NAFLD by Regulating gut Microbiota and GLP-1. Front Pharmacol 2021;12:693048. [PMID: 34276380 DOI: 10.3389/fphar.2021.693048] [Reference Citation Analysis]
120 Cani PD, Moens de Hase E, Van Hul M. Gut Microbiota and Host Metabolism: From Proof of Concept to Therapeutic Intervention. Microorganisms 2021;9:1302. [PMID: 34203876 DOI: 10.3390/microorganisms9061302] [Reference Citation Analysis]
121 Gómez-Hurtado I, Gallego-Durán R, Zapater P, Ampuero J, Aller R, Crespo J, Arias-Loste M, García-Monzón C, Bellot P, González-Rodríguez Á, Juanola O, Romero-Gómez M, Francés R. Bacterial antigen translocation and age as BMI-independent contributing factors on systemic inflammation in NAFLD patients. Liver Int 2020;40:2182-93. [PMID: 32559006 DOI: 10.1111/liv.14571] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
122 Fling RR, Zacharewski TR. Aryl Hydrocarbon Receptor (AhR) Activation by 2,3,7,8-Tetrachlorodibenzo-p-Dioxin (TCDD) Dose-Dependently Shifts the Gut Microbiome Consistent with the Progression of Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2021;22:12431. [PMID: 34830313 DOI: 10.3390/ijms222212431] [Reference Citation Analysis]
123 Wei L, Yue F, Xing L, Wu S, Shi Y, Li J, Xiang X, Lam SM, Shui G, Russell R, Zhang D. Constant Light Exposure Alters Gut Microbiota and Promotes the Progression of Steatohepatitis in High Fat Diet Rats. Front Microbiol 2020;11:1975. [PMID: 32973715 DOI: 10.3389/fmicb.2020.01975] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
124 Adams LA, Wang Z, Liddle C, Melton PE, Ariff A, Chandraratna H, Tan J, Ching H, Coulter S, de Boer B, Christophersen CT, O'Sullivan TA, Morrison M, Jeffrey GP. Bile acids associate with specific gut microbiota, low-level alcohol consumption and liver fibrosis in patients with non-alcoholic fatty liver disease. Liver Int 2020;40:1356-65. [PMID: 32243703 DOI: 10.1111/liv.14453] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
125 Ding X, Jian T, Li J, Lv H, Tong B, Li J, Meng X, Ren B, Chen J. Chicoric Acid Ameliorates Nonalcoholic Fatty Liver Disease via the AMPK/Nrf2/NFκB Signaling Pathway and Restores Gut Microbiota in High-Fat-Diet-Fed Mice. Oxid Med Cell Longev 2020;2020:9734560. [PMID: 33204402 DOI: 10.1155/2020/9734560] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
126 Li R, Andreu-Sánchez S, Kuipers F, Fu J. Gut microbiome and bile acids in obesity-related diseases. Best Pract Res Clin Endocrinol Metab 2021;35:101493. [PMID: 33707081 DOI: 10.1016/j.beem.2021.101493] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 7.0] [Reference Citation Analysis]
127 Moreno-Gonzalez M, Beraza N. The Role of the Microbiome in Liver Cancer. Cancers (Basel) 2021;13:2330. [PMID: 34066064 DOI: 10.3390/cancers13102330] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
128 Huang W, Yan Y, Wu M, Hu J, Zhao J, Chen X, Liu W, Liu K, Li C. Preoperative fasting confers protection against intestinal ischaemia/reperfusion injury by modulating gut microbiota and their metabolites in a mouse model. Br J Anaesth 2021:S0007-0912(21)00754-6. [PMID: 34930601 DOI: 10.1016/j.bja.2021.11.025] [Reference Citation Analysis]
129 Caussy C, Aubin A, Loomba R. The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk. Curr Diab Rep 2021;21:15. [PMID: 33742318 DOI: 10.1007/s11892-021-01383-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
130 Chen J, Ding X, Wu R, Tong B, Zhao L, Lv H, Meng X, Liu Y, Ren B, Li J, Jian T, Li W. Novel Sesquiterpene Glycoside from Loquat Leaf Alleviates Type 2 Diabetes Mellitus Combined with Nonalcoholic Fatty Liver Disease by Improving Insulin Resistance, Oxidative Stress, Inflammation, and Gut Microbiota Composition. J Agric Food Chem 2021;69:14176-91. [PMID: 34783554 DOI: 10.1021/acs.jafc.1c05596] [Reference Citation Analysis]
131 Shen B, Wang J, Guo Y, Gu T, Shen Z, Zhou C, Li B, Xu X, Li F, Zhang Q, Cai X, Dong H, Lu L. Dextran Sulfate Sodium Salt-Induced Colitis Aggravates Gut Microbiota Dysbiosis and Liver Injury in Mice With Non-alcoholic Steatohepatitis. Front Microbiol 2021;12:756299. [PMID: 34795650 DOI: 10.3389/fmicb.2021.756299] [Reference Citation Analysis]
132 Wilkinson JE, Franzosa EA, Everett C, Li C, Hu FB, Wirth DF, Song M, Chan AT, Rimm E, Garrett WS, Huttenhower C; HCMPH researchers and trainees., HCMPH investigators. A framework for microbiome science in public health. Nat Med 2021;27:766-74. [PMID: 33820996 DOI: 10.1038/s41591-021-01258-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
133 Wu L, Li J, Feng J, Ji J, Yu Q, Li Y, Zheng Y, Dai W, Wu J, Guo C. Crosstalk between PPARs and gut microbiota in NAFLD. Biomed Pharmacother 2021;136:111255. [PMID: 33485064 DOI: 10.1016/j.biopha.2021.111255] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]